Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development and validation of its pipeline of prescription-based digital therapies. Swing Therapeutics’ near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.
External link for Swing Therapeutics, Inc.
San Francisco, CA 94105, US
Swing Therapeutics, Inc. reposted this
Thanks STAT and Mario Aguilar for covering the recent study of Stanza published in The Lancet and how Swing Therapeutics, Inc. is raising the bar for clinical study quality for digital therapies. As we aim for broad adoption for new technologies, establishing the evidence of clinical benefit is essential. https://lnkd.in/giKTkn7X
Thanks to Guilherme Torres Vilarino for the informative commentary on the publication in The Lancet this week: “The results found in the study are essential for professionals who care for patients with fibromyalgia [FM] as they present a new viable treatment alternative. Given the recommendation of multidisciplinary treatment for patients with FM, alternatives that can facilitate access are essential.” We’re honored to bring more awareness to #fibromyalgia with this publication—for providers looking for evidence-based treatments; for researchers looking to increase our collective knowledge about this complex condition; and for patients who are looking to live the life they want. Access the commentary here: https://lnkd.in/gKFMmA6Y Read the full release: https://lnkd.in/gfTCrFCU
Swing Therapeutics, Inc. reposted this
Positive phase 3 landmark study of a Digital Therapeutic (DTX)for Fibromyalgia! Published in The Lancet, the PROSPER-FM trial demonstrates that a 12-week, self-guided, smartphone-delivered digital acceptance and commitment therapy (ACT) program is both safe and effective for managing fibromyalgia in adults. Participants in the digital ACT group reported significantly greater improvement in their condition compared to those in the active control group, with 71% of ACT participants showing positive changes versus 22% in the control group. Statistical superiority was observed across nearly all endpoints, including the FIQ-R domains of “function,” “overall impact,” and “symptoms”; pain intensity and pain interference; the PROMIS Fatigue and Sleep Disturbance domains; the Beck Depression Inventory II (BDI II); the Psychological Inflexibility in Pain Scale (PIPS); and the Committed Action Questionnaire (CAQ-8). This opens the way to many new opportunities in non-pharmacologic therapy of fibromyalgia such as : treatment of early fibromyalgia or pre-fibromyalgia in at-risk patients (prevention), treat-to-target strategies, and more... See here the abstract: https://lnkd.in/eNBs3CFD
We’re thrilled to announce the publication in The Lancet of data from the Phase 3 trial of Stanza, a digital therapy for #fibromyalgia symptoms. This research validates Stanza’s clinical benefits for people with fibromyalgia, including improvements in well-being (measured by Patient Global Impression of Change), fibromyalgia severity (measured by the Revised Fibromyalgia Impact Questionnaire (FIQ-R)), and major fibromyalgia symptoms including pain intensity, pain interference, fatigue, sleep disturbance, depression and physical function, when compared to an active control. “Fibromyalgia options are typically limited to a handful of pharmacological interventions that have limited efficacy and that can come with difficult to manage side effects,” said Mike Rosenbluth, CEO of Swing. “This publication validates Stanza as a guideline-directed, non-drug approach that many patients previously couldn’t access, due to few available trained clinicians, geographic limitations, and cost. Read the full release: https://lnkd.in/gfTCrFCU Stanza is now available by prescription through Swing Care, a specialty clinic that offers comprehensive treatment for fibromyalgia. To learn more about Swing Care, visit www.swing.care
Swing has been selected for the 2024 UCSF Rosenman Innovators program, recognizing groundbreaking companies dedicated to advancing healthcare innovation! Read more from CEO Mike Rosenbluth ⬇️
I'm excited to announce that Swing has been selected for the 2024 UCSF Rosenman Innovators program! This prestigious program, as part of the UCSF Rosenman Institute, recognizes groundbreaking companies dedicated to advancing healthcare innovation, and I am honored to be part of such a visionary team at Swing Therapeutics, Inc. and Swing Care. Our selection as a #RosenmanInnovator is a testament to our commitment to transforming the healthcare landscape for patients with fibromyalgia and chronic pain conditions and making a positive impact on their lives. https://lnkd.in/gPu4SMtD
Don't miss out on the latest episode of the Digital Rheumatology Network podcast! In this episode, Dr. Mike Rosenbluth, CEO of Swing Therapeutics, unveils the FDA clearance journey for "Stanza," a groundbreaking digital therapeutic for Fibromyalgia. Joined by Prof. Stephen Gilbert from Dresden Technical University, they navigate the complexities of medical device regulatory science, shedding light on the path from clinical studies to market. For anyone passionate about the convergence of digital health solutions and regulatory pathways, this conversation is a must-listen: https://lnkd.in/evBfVZEP 🚀 #DigitalHealth #Rheumatology #RegulatoryScience
We were honored to be selected for the 2024 Society of Behavioral Medicine Citation Award, to deliver a podium presentation on the results from a pivotal randomized controlled trial of Stanza at the annual meeting last week. The presentation highlighted the potential for online Acceptance and Commitment Therapy to be an efficacious, accessible, and cost-effective treatment for people with #fibromyalgia and other chronic pain conditions. Read on for more results from Stanza and the latest outcomes from Swing Care.
New data alert! 🎉 Swing released new outcomes data from Swing Care, a telehealth clinic delivering multimodal treatment for #fibromyalgia, at the Society of Behavioral Medicine annual meeting last week. The results from Swing Care support meaningful improvement in well-being and reduced fibromyalgia severity among patients who received personalized treatment in the clinic: 🟢 At Day 30, 65% of the patients reported improvement in well-being, as measured by Patient Global Impression of Change (PGIC). 🟢 At Day 90, 81% of the patients reported improvement in well-being (PGIC). Improvements were also shown on additional clinical measures, including fibromyalgia severity, pain intensity and depression. 🟢 100% of Swing Care patients reported satisfaction with the clinic across the 90 days. Study authors were also selected for the 2024 SBM Citation Award to deliver a podium presentation on the results from a pivotal randomized controlled trial of Stanza, highlighting the potential for online Acceptance and Commitment Therapy (ACT) to be an efficacious, accessible, and cost-effective treatment for people with fibromyalgia and other chronic pain conditions. Thanks Dianne Shumay PhD for presenting our latest evidence at the meeting! See more results in the full post: https://lnkd.in/gJ3BhRva
Swing Therapeutics, Inc. reposted this
At the American Academy of Pain Medicine's annual meeting last week, Swing presented outcomes data on Swing Care, a specialty clinic for people with #fibromyalgia, as well as the results from a pivotal randomized controlled trial of Stanza, its prescription digital therapy for fibro. Results from a chart review of 199 Swing Care patients showed that clinical improvements were observed from Day 30 and increased in later followups, particularly in symptoms that patients most frequently reported to limit their quality of life (QoL), including pain, fatigue, “fibro fog”, difficulty sleeping, and difficulty moving. Learn more about Swing Care and its patient-centered approach to fibromyalgia care in our blog post: https://lnkd.in/gWViehTe
Join us for Digital Rheumatology Network’s sessions this Saturday, March 9, at the 6th Annual Digital Rheumatology Days! Swing Founder and CEO Mike Rosenbluth presents on digital behavioral therapies for #fibromyalgia outcomes, sharing the results from our PROSPER-FM randomized controlled trial for Stanza. Stanza, an FDA-cleared digital therapy for treatment of fibromyalgia symptoms, is now available by prescription. Learn more: https://lnkd.in/gxAja8fS See the full program: https://lnkd.in/eXzi8NzC
Last month, Swing Therapeutics presented data from a real-world trial of Stanza, an FDA-cleared digital behavioral therapy for treatment of #fibromyalgia symptoms, at the 2023 annual meeting of the Association for Behavioral and Cognitive Therapies. The results demonstrated Stanza’s clinically meaningful benefit in addressing unmet needs for fibromyalgia patients, specifically, showing the treatment’s impact on symptoms that most limit patient quality of life (QoL). After using the smartphone-based treatment, which provides Acceptance of Commitment Therapy and additional cognitive behavioral therapy-based interventions, 87% of participants improved in at least one QoL-limiting symptom. 3x patients reported QoL satisfaction after treatment. See the full post below, and learn more about the benefits of personalized, patient-centered care in addressing fibromyalgia symptoms.